Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#151 / 200 Total
DWTX - Dogwood Therapeutics Inc - Stock Price Chart
TickerDWTX [NASD]
CompanyDogwood Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap11.54MEPS (ttm)-6.31
P/E-EPS this Y17.73%
Forward P/E-EPS next Y41.94%
PEG-EPS past 5Y-2.02%
P/S-EPS next 5Y32.44%
P/B7.06EPS Q/Q-27.03%
Dividend-Sales Q/Q-
Insider Own18.63%Inst Own1.61%
Insider Trans0.00%Inst Trans-8.39%
Short Float1.69%EarningsMar 14/b
Analyst Recom1.00Target Price30.00
Avg Volume3.73M52W Range1.62 - 29.28
Mar-18-25 08:45AM Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron in Patients with Chemotherapy-Induced Neuropathic Pain (GlobeNewswire) -6.90%
Mar-14-25 12:15PM Biotech Alert: Searches spiking for these stocks today (TipRanks) -20.83%
Mar-13-25 09:00AM Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -27.76%
Mar-12-25 08:30AM Dogwood Therapeutics, Inc. Announces Conversion of Existing $19.5M in Debt to Equity, Strengthening Balance Sheet Moving Forward (GlobeNewswire)
Jan-21-25 09:15AM Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025 (GlobeNewswire) +68.45%
Nov-18-24 08:45AM Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study (GlobeNewswire) -37.71%
Nov-08-24 02:35AM Q3 2024 Dogwood Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
02:15AM Dogwood Therapeutics Inc (DWTX) Q3 2024 Earnings Call Highlights: Strategic Financing and ... (GuruFocus.com)
Nov-07-24 07:05AM Dogwood Therapeutics Announces Third Quarter 2024 Financial Results (GlobeNewswire)
Oct-31-24 09:15AM Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024 (GlobeNewswire)
Dogwood Therapeutics, Inc. is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia. The company was founded on February 28, 2012 is headquartered in Alpharetta, GA.
DNA - Ginkgo Bioworks Holdings Inc - Stock Price Chart
TickerDNA [NYSE]
CompanyGinkgo Bioworks Holdings Inc
CountryUSA
IndustryBiotechnology
Market Cap417.26MEPS (ttm)-10.62
P/E-EPS this Y49.93%
Forward P/E-EPS next Y29.24%
PEG-EPS past 5Y-27.97%
P/S1.84EPS next 5Y48.92%
P/B0.52EPS Q/Q53.33%
Dividend-Sales Q/Q26.16%
Insider Own32.80%Inst Own57.91%
Insider Trans-0.04%Inst Trans20.18%
Short Float24.51%EarningsFeb 25/a
Analyst Recom3.83Target Price8.60
Avg Volume1.66M52W Range5.26 - 48.00
Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Che AustinOfficerMar 25 '25Proposed Sale7.7599767Mar 25 09:51 AM
Che AustinOfficerMar 24 '25Proposed Sale7.5399745Mar 24 09:53 AM
Che AustinOfficerMar 21 '25Proposed Sale7.0099693Mar 21 09:44 AM
Che AustinOfficerMar 20 '25Proposed Sale7.4099733Mar 20 09:42 AM
Che AustinOfficerMar 19 '25Proposed Sale7.2799720Mar 19 09:42 AM
AKYA - Akoya Biosciences Inc - Stock Price Chart
TickerAKYA [NASD, RUT]
CompanyAkoya Biosciences Inc
CountryUSA
IndustryMedical Instruments & Supplies
Market Cap77.71MEPS (ttm)-1.12
P/E-EPS this Y43.30%
Forward P/E-EPS next Y20.08%
PEG-EPS past 5Y-23.03%
P/S0.95EPS next 5Y25.67%
P/B10.18EPS Q/Q24.82%
Dividend-Sales Q/Q-19.42%
Insider Own58.34%Inst Own24.65%
Insider Trans0.00%Inst Trans-5.63%
Short Float17.46%EarningsMar 17/a
Analyst Recom3.00Target Price3.17
Avg Volume685.32K52W Range1.39 - 5.00
Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery and clinical research. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers two distinct solutions, the CODEX and Phenoptics platforms, to serve the diverse needs of researchers across discovery, translational and clinical research. The company was founded by Garry Nolan, Yury Goltsev and Nikolay Samusik in 2015 and is headquartered in Marlborough, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
McKelligon BrianPresident and CEOJun 11 '24Option Exercise0.307,5002,272232,233Jun 12 04:01 PM
McKelligon BrianPresident and CEOJun 11 '24Sale2.087,50015,630224,733Jun 12 04:01 PM
McKelligon BrianPresident and CEOJun 06 '24Option Exercise0.307,5002,272232,233Jun 07 09:56 PM
McKelligon BrianPresident and CEOJun 06 '24Sale2.017,50015,064224,733Jun 07 09:56 PM
IMVT - Immunovant Inc - Stock Price Chart
TickerIMVT [NASD, RUT]
CompanyImmunovant Inc
CountryUSA
IndustryBiotechnology
Market Cap3.08BEPS (ttm)-2.62
P/E-EPS this Y-49.95%
Forward P/E-EPS next Y-8.41%
PEG-EPS past 5Y-
P/S-EPS next 5Y-21.29%
P/B7.58EPS Q/Q-112.56%
Dividend-Sales Q/Q-
Insider Own59.16%Inst Own47.38%
Insider Trans19.94%Inst Trans6.13%
Short Float22.19%EarningsFeb 06/b
Analyst Recom1.29Target Price45.83
Avg Volume1.42M52W Range17.01 - 34.47
Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Fromkin Andrew J.DirectorMar 07 '25Sale19.608,000156,76991,913Mar 11 04:18 PM
ANDREW J FROMKINDirectorMar 07 '25Proposed Sale19.528,000156,160Mar 07 04:17 PM
Macias William L.Chief Medical OfficerFeb 19 '25Sale20.862,05542,867357,353Feb 21 04:06 PM
Barnett Eva ReneeChief Financial OfficerFeb 19 '25Sale20.862,81458,700321,952Feb 21 04:05 PM
Salzmann PeterChief Executive OfficerFeb 19 '25Sale20.8615,439322,058948,786Feb 21 04:04 PM
IH - iHuman Inc ADR - Stock Price Chart
TickerIH [NYSE]
CompanyiHuman Inc ADR
CountryChina
IndustryEducation & Training Services
Market Cap56.68MEPS (ttm)0.27
P/E9.01EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S0.43EPS next 5Y-
P/B0.96EPS Q/Q-50.38%
Dividend-Sales Q/Q-7.44%
Insider Own-Inst Own0.72%
Insider Trans-Inst Trans11.95%
Short Float-EarningsDec 26/b
Analyst Recom1.00Target Price3.67
Avg Volume77.01K52W Range1.47 - 3.18
iHuman, Inc. engages in the development of techno-powered applications for children. The company was founded by Yu Feng Chi in March 2016 and is headquartered in Beijing, China.
FTRE - Fortrea Holdings Inc - Stock Price Chart
TickerFTRE [NASD]
CompanyFortrea Holdings Inc
CountryUSA
IndustryBiotechnology
Market Cap792.41MEPS (ttm)-3.45
P/E-EPS this Y51.20%
Forward P/E9.68EPS next Y81.98%
PEG-EPS past 5Y3.94%
P/S0.29EPS next 5Y65.39%
P/B0.58EPS Q/Q-78.19%
Dividend-Sales Q/Q-10.11%
Insider Own0.36%Inst Own104.45%
Insider Trans-5.42%Inst Trans-14.05%
Short Float7.67%EarningsMar 03/b
Analyst Recom2.92Target Price11.70
Avg Volume1.69M52W Range8.65 - 40.63
Fortrea Holdings, Inc. engages in the provision of clinical development and commercialization services. It operates under the Clinical Services and Enabling Services Segments. The Clinical Services segment provides services across the clinical pharmacology, clinical development, and other clinical service spectrum utilizing enabling services and technology through multiple delivery models. The Enabling Services segment provides technology solutions directly to customers that streamline complex randomization and optimize the trial drug supply process, while minimizing operational costs and supporting timely and accurate patient dosing. The company was founded on January 31, 2023 and is headquartered in Durham, NC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hanson James S.General CounselMar 13 '25Option Exercise0.002,998010,473Mar 17 04:37 PM
Hanson James S.General CounselMar 14 '25Sale9.701,0079,7689,466Mar 17 04:37 PM
Morais Mark A.Chief Operating OfficerMar 13 '25Option Exercise0.004,283039,879Mar 17 04:35 PM
Morais Mark A.Chief Operating OfficerMar 14 '25Sale9.701,20711,70838,672Mar 17 04:35 PM
Mcconnell Jill G.Chief Financial OfficerMar 13 '25Option Exercise0.004,283041,677Mar 17 04:33 PM
SYRE - Spyre Therapeutics Inc - Stock Price Chart
TickerSYRE [NASD, RUT]
CompanySpyre Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap1.07BEPS (ttm)-3.16
P/E-EPS this Y-12.04%
Forward P/E-EPS next Y-2.64%
PEG-EPS past 5Y44.65%
P/S-EPS next 5Y-5.20%
P/B2.96EPS Q/Q-106.83%
Dividend-Sales Q/Q-
Insider Own15.13%Inst Own93.76%
Insider Trans-0.08%Inst Trans21.13%
Short Float19.60%EarningsFeb 27/a
Analyst Recom1.27Target Price55.11
Avg Volume600.96K52W Range17.24 - 43.00
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Albers Jeffrey W.DirectorNov 06 '24Sale36.766,700246,31327,360Nov 08 04:53 PM
Albers Jeffrey W.DirectorOct 25 '24Sale36.4330010,92934,060Oct 28 04:41 PM
SESSIONS, LLCDirectorOct 25 '24Proposed Sale33.707,000235,900Oct 25 04:28 PM
Burrows Scott LChief Financial OfficerSep 03 '24Sale28.1718,531522,074116,422Sep 05 04:04 PM
Fairmount Funds Management LLCDirectorApr 25 '24Option Exercise0.003,639,68004,018,101Apr 25 04:55 PM
AIFF - Firefly Neuroscience Inc - Stock Price Chart
TickerAIFF [NASD]
CompanyFirefly Neuroscience Inc
CountryUSA
IndustrySoftware - Application
Market Cap35.92MEPS (ttm)-2.04
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-88.86%
P/S4.64EPS next 5Y-
P/B13.59EPS Q/Q-267.27%
Dividend-Sales Q/Q-98.37%
Insider Own59.13%Inst Own12.70%
Insider Trans0.00%Inst Trans41.68%
Short Float13.54%Earnings-
Analyst Recom-Target Price-
Avg Volume9.08M52W Range1.86 - 17.20
Firefly Neuroscience, Inc. is an artificial intelligence (AI) technology company, which engages in developing neuroscientific solutions for mental illnesses and neurological disorders. It offers Brain Network Analytics (BNA) platform, a software as a medical solution for the diagnostic and treatment methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. The company was founded in 1979 and is headquartered in Kenmore, NY.
TIL - Instil Bio Inc - Stock Price Chart
TickerTIL [NASD]
CompanyInstil Bio Inc
CountryUSA
IndustryBiotechnology
Market Cap119.03MEPS (ttm)-11.39
P/E-EPS this Y1.45%
Forward P/E-EPS next Y-30.91%
PEG-EPS past 5Y-62.10%
P/S-EPS next 5Y11.18%
P/B0.70EPS Q/Q8.28%
Dividend-Sales Q/Q-
Insider Own49.08%Inst Own36.95%
Insider Trans0.00%Inst Trans-4.17%
Short Float15.90%EarningsMar 04/b
Analyst Recom1.75Target Price113.67
Avg Volume92.01K52W Range9.62 - 92.00
Instil Bio, Inc. is a clinical-stage biopharmaceutical company engaged in developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte therapies for the treatment of patients with cancer. The company was founded in August 2018 and is headquartered in Dallas, TX.
FCUV - Focus Universal Inc - Stock Price Chart
TickerFCUV [NASD]
CompanyFocus Universal Inc
CountryUSA
IndustryScientific & Technical Instruments
Market Cap32.73MEPS (ttm)-0.47
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y1.61%
P/S72.73EPS next 5Y-
P/B10.30EPS Q/Q-9.77%
Dividend-Sales Q/Q-52.83%
Insider Own52.97%Inst Own3.24%
Insider Trans0.00%Inst Trans-25.95%
Short Float3.07%Earnings-
Analyst Recom-Target Price4.50
Avg Volume626.68K52W Range1.50 - 10.90
Focus Universal, Inc. engages in the development and manufacture of universal smart devices. Its technology features a Universal Smart Instrumentation Platform (USIP), a hardware and software integration platform that provides solutions for embedded design, industrial control and monitoring. It also offers Ubiquitor, universal smart controller, and sensors. The company was founded by Desheng Wang on December 4, 2012 and is headquartered in Ontario, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
WANG DESHENGCEO and DirectorSep 18 '24Buy0.301,000,000300,00022,729,550Sep 18 07:27 PM
Lee Edward ShihaiPresident and DirectorSep 18 '24Buy0.301,000,000300,0009,185,000Sep 18 07:25 PM
WANG DESHENGCEO and DirectorAug 28 '24Buy0.18280,10050,51821,898,650Aug 29 03:59 PM
WANG DESHENGCEO and DirectorAug 27 '24Buy0.1822,0003,98021,618,500Aug 29 03:59 PM
11011121314151617181920